Veradermics R&D Chief Gets Equity as Insiders Cashed Out
Veradermics' Chief R&D Officer received a fresh equity grant on September 1, just days after the company's CEO, CTO, board director, and largest shareholder collectively sold $103 million in stock at
Veradermics R&D Chief Gets Equity as Insiders Cashed Out
NEW YORK, September 4 —
Veradermics, Incorporated (MANE) gave its Chief R&D Officer a fresh equity grant on September 1, days after the CEO, CTO, a director, and its largest shareholder collectively sold $103.12 million of stock at prices between $106.14 and $111.28 per share, none of which the stock has seen since. At $98.31 today, every insider exit cleared above the current price.
- $103.12M in combined insider sales Aug 12-19; stock now at $98.31, below every exit price.
- CRO David Hollander received 9,650 shares on Sept 1, the only insider equity receipt in the 90-day period.
- $820M cash, no debt; approximately $78M annual cash burn; analyst consensus target $163.50, 66% above current price.
The Exit Sequence
Veradermics filed an S-1 registration statement on August 7, three days before its August 11 earnings release, which posted a 9.4% EPS beat against consensus, a turnaround from a prior quarter that recorded actual EPS of -$104.54 against an estimate of -$18.24, likely a one-time charge. A 424B3 prospectus followed three days after that 8-K. Sandwiched in that ten-day window, director John Childs, CEO Reid Waldman, CTO Timothy Durso, and Montanova Capital each sold at prices between $106.14 and $111.28, all above where Veradermics now trades.
Ten Years of Runway, Zero Revenue
Veradermics, incorporated in 2019, is a 37-employee clinical-stage biotech with no commercial products. Its lead candidate, VDPHL01, is an oral non-hormonal treatment for androgenetic alopecia, pattern hair loss in both men and women, with a pipeline that also covers alopecia areata, molluscum contagiosum, and warts. The company burns approximately $78 million in cash annually but holds $820 million and no debt, providing roughly a decade of runway. The Wall Street consensus sits about 66% above today's price, a gap that prices in pipeline progress the company has not yet delivered commercially.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| MANE | $4.1B | n/a | +158.9% |
| ORKA | $6.1B | n/a | +456.5% |
| SYRE | $7.8B | n/a | +413.2% |
| COAG | $2.1B | n/a | +30.5% |
| KLRA | $2.1B | n/a | -39.5% |
| DNTH | $6.0B | n/a | +307.0% |
What Hollander's Grant Leaves Open
The straightforward read of Chief R&D Officer David Hollander's 9,650-share grant is scientific conviction: equity accepted at prices his colleagues had already cleared. Montanova Capital complicates the picture; the firm sold $80.44 million on August 19 and exercised options for 300,000 additional shares the next day, replacing near-term exposure with longer-dated optionality at lower strikes. The key checkpoint is any VDPHL01 clinical data release; progress would frame Hollander's grant as signal and put the $163.50 analyst target in play. Run the free Veradermics, Incorporated deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Veradermics' Chief R&D Officer received a fresh equity grant on September 1, just days after the company's CEO, CTO, board director, and largest shareholder collectively sold $103 million in stock at prices that have since fallen to $98.31. The split insider signal — one executive aligning interests while peers cashed out — leaves the stock's direction unresolved.